治疗途径抗发炎药市场 - 技术，适应症，市场与预测

Therapeutic Pathway Anti-Inflammatory Drugs & Markets, Technology, Indications, Markets & Forecasts

出版日期: 2025年03月31日 | 出版商:

Greystone Research Associates | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

本市场研究报告对推动药物传输领域这一不断增长的技术、产品和市场参与者进行了全面的评估和分析。本报告旨在让製药决策者、药物开发商和配方师、药物设备设计师和产业策略家详细了解吸入式中枢神经系统治疗对製药策略和医疗保健治疗方案日益增长的影响。它对于医疗保健组织的业务经理、医疗保健管理人员和投资者也将很有用。

多种驱动因子

向中枢神经系统注射药物面临独特的挑战。然而，药物开发商和研究人员发现，透过吸入方式输送中枢神经系统药物可以缓解其中的一些问题。鼻腔通路和血管系统为将小分子药物和生物製剂穿过血脑屏障输送到中枢神经系统提供了一个有吸引力的途径。深肺给药可能具有良好的药物动力学特性。与口服药物相比，吸入给药还可以提供更快的起效速度，且所需的给药频率更低。这些潜在的益处促进了针对多种疾病的吸入式中枢神经系统药物的开发。随着人口老化和管理式医疗计划促使家庭医疗保健和药物自我管理的扩大，吸入药物越来越被视为对患者友好且具有成本效益的药物。我们的分析表明，透过吸入进行中枢神经系统输送非常适合利用这些趋势，并发展成为未来药物开发和中枢神经系统治疗商业化的关键组成部分。

IL-23/IL-17 轴作为自体免疫的治疗标靶 IL-23/IL-17 轴在人类自体免疫疾病中变得重要，从而促使新型治疗药物的批准和快速开发。针对各种细胞激素或细胞激素受体的单株抗体以及针对 RORyt 和 JAK 的小分子抑制剂正在改变治疗格局，目前已有三十多种不同的产品获得批准或处于临床开发阶段。针对 IL-17 和 IL-17RA 的人源化单株抗体能够改善中度至重度干癣和干癣关节炎的治疗效果。

您将学到什么

哪些吸入药物以粉末形式提供，它们如何分发，有哪些设备，以及谁在分发它们？
哪些吸入干粉药物处于后期开发阶段，谁在开发这些药物，以及用于哪些适应症？
推动吸入干粉药物/设备需求的关键因素有哪些？
目前的市场规模是多少，谁是市占率领先者，以及他们在 2024 年的市占率将会是多少？
药品开发商和设备製造商之间的关係有多重要？该行业的主要联盟有哪些？
干粉吸入产品的关键设计因素、技术和市场发展挑战是什么？
影响干粉吸入器市场的关键经济、技术和监管因素有哪些？

调查方法：

该研究方法以对主要市场参与者、技术开发商、分销商、行业专家和市场影响者（包括监管机构、行业协会和材料标准机构）进行深入访谈的形式进行初步研究。

根据行业期刊文章、技术文献、行业出版物、公司数据表和公开声明以及政府机构和行业协会的统计数据等二手资料来源对主要资讯进行评估和标准化。

使用标准建模和统计技术可以估计和预测市场需求和未来市场活动。

摘要整理
Th17途径
针对 Th17 发炎路径级联
白细胞介素 6 (IL-6)
已核准的药物
正在研发的药物
白血球介素 IL-6R
已核准的药物
正在研发的药物
Janus激酶/酪胺酸激酶抑制剂
已核准的药物
正在研发的药物
讯号蛋白
讯号传导和转录活化因子 (STATs)
白血球介素-21 (IL-21)
白血球介素-21受体 (IL-21R)
白血球介素-23 (IL-23)
已核准的药物
正在研发的药物
白血球介素-23受体 (IL-23R)
白血球介素-17A (IL-17A)
已核准的药物
白血球介素-17C (IL-17C)
正在研发的药物
白血球介素 17A/17F
正在研发的药物
白介素-17RA (IL-17RA)
已核准的药物
转化生长因子-β RI/RII (TGF-β RI/RII)
正在研发的药物
视黄酸相关孤儿受体RORyt
正在研发的药物
白细胞介素17
正在研发的药物
白细胞介素-22（IL-22）
市场状况
市场规模
竞争情势
Th17 路径介导的发炎性疾病
最大可寻址市场规模
竞争情势
市场参与企业的简介

简介目录

This new market study, "Therapeutic Pathway Anti-Inflammatory Drugs & Markets" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of inhaled CNS therapies on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving

Delivering drugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicated that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

The IL-23/IL-17 axis as a therapeutic target in autoimmunity The identification of the IL-23/IL-17 axis as critical for human autoimmune disease has led to the approval and rapid development of novel therapeutic agents. Monoclonal antibodies to a variety of cytokines and cytokine receptors and small-molecule inhibitors of RORyt and JAKs are changing the therapeutic landscape, with three dozen distinct products now approved or in clinical development. Humanized monoclonal antibodies to both IL-17 and IL-17RA are enabling improved outcomes for moderate to severe psoriasis as well as psoriatic arthritis.

What You Will Learn:

What inhalable drugs are supplied in powder form, how are they marketed, what are the device specifics, and who markets them?
What inhalable dry powder drugs are in late stage development, who are the developers, and what indications are they targeting?
What are the major factors driving inhaled dry powder drug/device demand?
What is the size of the market today, who are the market share leaders, and what will the market share be in 2024?
How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
What are the essential design factors, technologies and market development issues for dry powder inhalation products?
What are the significant economic, technology, and regulatory factors affecting the market for dry powder inhalers?

Methodology:

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.